Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03525405
Other study ID # BBI608-104
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 18, 2018
Est. completion date June 2, 2018

Study information

Verified date November 2023
Source Sumitomo Pharma America, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I, single-center, open-label, single-sequence, study evaluating the absorption, metabolism, and excretion of napabucasin in healthy adult male volunteers using a mixture 14C-radiolabeled and unlabeled material.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date June 2, 2018
Est. primary completion date June 2, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion criteria 1. An Institutional Review Board (IRB) approved informed consent is signed and dated prior to any study-related activities. 2. Subject is male. 3. Subject is between the ages of 18 and 45 years, inclusive at screening. 4. Subject has a body mass index between 18 and 34 kg/m^2 (weight/[height]^2) inclusive at screening. 5. Subject has normal (or abnormal and clinically insignificant according to the Investigator) laboratory values at screening. 6. Subject is in good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs measurements, or clinical laboratory evaluations at Screening or Check-in Day -1 as assessed by the Investigator (or designee). Subject has the ability to understand the requirements of the study and a willingness to comply with all study procedures. 7. Subject has not consumed and agrees to abstain from taking any dietary supplements, herbal products, and non-prescription drugs (except as authorized by the Investigator and Medical Monitor) for 14 days prior to clinical research unit (CRU) admission through follow-up call. 8. Subject has not consumed and agrees to abstain from taking any prescription drugs (except as authorized by the Investigator and Medical Monitor) during the 14 days prior to CRU admission through follow-up call. 9. Subject has not consumed alcohol-containing beverages for 3 days prior to CRU admission and agrees not to consume alcohol through clinic discharge. 10. Subject has not consumed char-broiled meats, cruciferous vegetables, and grapefruit-, apple-, or Seville orange-containing products within the 3 days prior to CRU admission and agrees not to consume Seville oranges, grapefruit and grapefruit juice through clinic discharge. 11. Subject has not used tobacco- and nicotine-containing products within 2 months prior to the CRU admission and agrees to abstain from using tobacco- and nicotine-containing products through clinic discharge. 12. Subject agrees to abstain from consuming caffeine- or xanthine-containing products from 3 days prior to CRU admission through clinic discharge. 13. History of a minimum of 1 bowel movement per day Exclusion criteria 1. Subject has a history of illicit drug abuse in the past year or displays current evidence of such abuse in the opinion of the Investigator. 2. Subject has positive findings on urine drug screen (including cotinine). 3. Subject is positive for human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C on Screening assessments. 4. Subject has a QTcF >450 msec at screening (confirmed by repeat). 5. Subject has a female partner who is either pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of the study drug, or unwilling to follow the contraception requirements. 6. Subject has a clinically significant acute illness within 1 week of CRU admission, or symptoms of active illness at check-in, at discretion of the Investigator (or designee). 7. Subject has a hypersensitivity or allergy to napabucasin or the ingredients of napabucasin, or other clinically significant allergies in the opinion of the Investigator. 8. Subject has donated plasma within 7 days of drug administration. 9. Subject has donated 1 or more pints of blood (or equivalent blood loss) within 30 days prior to drug administration. 10. Subject has a history of chronic Gastroesophageal reflux disease (GERD) or has used omeprazole or other proton pump inhibitors within 3 months of Screening. 11. Subject has congenital non-hemolytic hyperbilirubinemia [e.g., Gilbert's syndrome]. 12. Subject has any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy, or other gastrointestinal tract surgery, except appendectomy). 13. Subject has participated in an investigational drug study within 30 days or 5 half-lives (whichever is longer) of exposure to another investigational medication prior to CRU admission. 14. Subject is an employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, or a family member of the employees or the Investigator. 15. Subjects with exposure to significant diagnostic or therapeutic radiation (e.g., serial Xray, computed tomography scan, barium meal) or employment in a job requiring radiation exposure monitoring within 12 months prior to check-in. 16. Subjects who have participated in a radiolabeled drug study where exposures are known to the Investigator within the previous 4 months prior to admission to the clinic for this study or participated in a radiolabeled drug study where exposures are not known to the Investigator within the previous 6 months prior to admission to the clinic for this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
napabucasin
Single 240 mg dose containing 100 µCi of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.

Locations

Country Name City State
United States Covance Clinical Research Unit Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
Sumitomo Pharma America, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pharmacokinetics for napabucasin and metabolites by assessing plasma concentration 1 week
Primary Pharmacokinetics for napabucasin and metabolites by assessing urinary concentration Up to 12 days
Primary Pharmacokinetics for napabucasin and metabolites by assessing fecal concentration Up to 12 days
Secondary Number of Patients with Adverse Events 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1